9 results about "Antigen response" patented technology

The present disclosure provides methods for identifying T-cell receptors (TCRs) from sequencing data, and TCR sequences identified using the methods. The methods can comprise identifying a TCR alpha chain, a TCR beta chain, a TCR gamma chain, or a TCR delta chain from the sequencing data, and then identifying the corresponding paired chain. The "de novo" method can comprise the identification of statistically associated TCR chain sequences by assessing patients' antigenic status and / or HLA alleles. In the "bait" method, a TCR chain sequence of a TCR known to have some degree of antigen reactivity can be used to search for related sequences in the large database. Resulting sequences may or may not exhibit statistical enrichments that can be detected using the "de novo" approach. Various pairing methods are provided. Identified paired TCR chains can be used for preparing various therapies including cell-based therapies.

Provided herein are CasX:gNA systems, and compositions and methods relating thereto, the systems comprising CasX proteins, guide nucleic acids (gNAs), and optionally donor template nucleic acids useful for the modification cell genes encoding proteins involved in antigen processing, antigen presentation, antigen recognition, and / or antigen response, as well as methods of producing and using populations of cells comprising these modified genes. In some embodiments, the modified cells further express chimeric antigen receptors (CAR) or engineered T cell receptors (TCR). Such systems are useful for preparing cells for immunotherapy.

To provide an antigen responsiveness enhancer. [Solution] From Euglena, paramylon, paramylon processed product, and β-1,3-glucan An antigen response enhancer containing at least one selected from the group.

The present disclosure relates generally to antibodies reactive with tumor-specific neoantigens, as well as neoantigen-binding fragments thereof. The present disclosure also relates to nucleic acids, expression cassettes, and expression vectors encoding the antibodies and neoantigen-binding fragments. The antibodies and neoantigen binding-fragments are useful for diagnosis and treatment of cancer.

The present invention relates to compositions for detecting a lung cancer disease, comprising peptide affinity ligands for detecting different combinations of proteins of different groups of biomarkers which include CYFRA 21-1, Prolactin, Squamous Cell Carcinoma Antigen (SCC), Her2 / Neu, Cancer antigen 125 (CA125), carcinoembryonic antigen (CEA), C- reactive protein (CRP), Neuron Specific Enolase (NSE), C4 complement (C4), Interleukin 6 (IL-6), and Metallopeptidase Inhibitor 1 (TIMP-1). The invention further relates to methods of detecting or subtyping lung diseases, as well as to computer-implemented methods based on machine learning methods using expression data of the biomarkers.

This invention relates to a genetically engineered bacterial outer membrane vesicle and its preparation method. By using in-cell peptides to attach exogenous proteins to the surface of OMVs via peptide bonds, a variety of desired antigens can be conveniently delivered. The reaction conditions are mild, less affected by antigen size, and unlike the SpyCatcher / SpyTag system, the in-cell peptides do not remain in the mature protein after attaching the exogenous protein to the OMV surface. This invention can serve as a universal tool for simultaneously or separately displaying different antigens on the surface of OMVs.

This invention relates to the field of tumor vaccines, specifically to an anti-tumor vaccine, its preparation method, and its application. The invention prepares an anti-tumor vaccine, BCG-CW@LNT, by mixing cell walls extracted from BCG vaccine as an immune adjuvant with LNT cells obtained from tumor cells through rapid freeze-thaw cycles in liquid nitrogen. This vaccine utilizes these "therapeutic dead cells" to induce a broad antigen response throughout the entire cell, mimicking the natural presentation of antigens in the tumor microenvironment, thereby enhancing anti-cancer immunity. In bladder cancer and lung cancer models, BCG-CW@LNT demonstrated good anti-tumor therapeutic effects. Furthermore, due to the presence of memory T cells, it exhibits a long-term memory effect, providing long-term anti-tumor and preventative effects, effectively preventing tumor recurrence and offering a novel option for tumor treatment.

Various embodiments of the invention provide compositions of tumor infiltrating lymphocytes (TILs) enriched in tumor reactive cells, methods for manufacturing TILs enriched in tumor reactive cells and methods and uses of the provided enriched tumor reactive TILs for treating cancer in a human or other subject. Among the provided embodiments of TIL compositions may include those that exhibit substantial tumor reactivity activity, including degranulation and the ability to express one or more of IFN-gamma and TNF-alpha, in response to antigen presenting cells presenting neo antigenic peptides.

Disclosed is a method of providing antigen-reactive lymphocytes comprising: (a) obtaining lymphocytes of an individual wherein the individual carries at least one antigen; (b) establishing a primary culture of lymphocytes; (c) introducing a transient reporter system into the lymphocytes of the primary culture, wherein the reporter system generates a signal upon activating the nuclear translocation of the T cell nuclear factor (NFAT); (d) attacking the lymphocytes with at least one antigen; and (e) screening at least one antigen-reactive lymphocyte from the lymphocytes by detecting the signal. Also disclosed are pharmaceutical compositions comprising amplified antigen-reactive lymphocytes obtained by the method and kits for performing the method.